How Often Should CRP Be Tested?: A Functional-Medicine Interpretation Guide

Why CRP Deserves More Than a One-Time Check

C-reactive protein (CRP) is a protein produced by the liver in response to inflammation anywhere in the body. In conventional medicine, it is typically ordered when a doctor suspects an acute infection or autoimmune flare. In functional and preventive medicine, however, high-sensitivity CRP (hs-CRP) is treated as a continuous, modifiable risk variable — one that predicts cardiovascular events, metabolic disease, cognitive decline, and all-cause mortality independently of cholesterol or blood pressure.

The landmark JUPITER trial (Ridker et al., New England Journal of Medicine 2008; PMID: 19005196) enrolled nearly 18,000 participants with normal LDL cholesterol but elevated hs-CRP (≥2.0 mg/L) and demonstrated that statin therapy reduced cardiovascular events by 44% in this group — a finding that reframed CRP from a curiosity to a clinical imperative. If CRP predicts risk even when cholesterol looks fine, then knowing your number once is not enough.

What the Numbers Actually Mean

Not all CRP tests are equal. Standard CRP is designed to detect high-level inflammation (infections, trauma, autoimmune flares) and is typically reported in milligrams per deciliter (mg/dL). High-sensitivity CRP (hs-CRP) is calibrated for the lower ranges relevant to cardiovascular and metabolic risk and is reported in mg/L.

The American Heart Association and the Centers for Disease Control and Prevention co-published guidance establishing < 1.0 mg/L as low risk and > 3.0 mg/L as high risk for cardiovascular disease (Pearson et al., Circulation 2003; PMID: 12551878). Functional practitioners often use the more refined < 0.5 mg/L as an "optimal" target, particularly in patients with metabolic syndrome, obesity, or a family history of early heart disease.

How Often Should CRP Be Tested for Ongoing Monitoring?

The right retesting frequency depends entirely on your current level and what is being done about it:

1. If hs-CRP is optimal (< 0.5 mg/L): Once per year alongside your standard metabolic panel is sufficient. Inflammation at this level is rarely a driver of acute risk.

1. If hs-CRP is 1.0 – 3.0 mg/L: Retest every 3 months until two consecutive readings confirm a downward trend. One elevated result could be confounded by a recent illness or intense exercise — guidelines recommend averaging two measurements taken 2 weeks apart before making therapeutic decisions (Pearson et al., Circulation 2003; PMID: 12551878).

1. If hs-CRP is > 3.0 mg/L and an intervention has started: Retest at 6–8 weeks to assess whether dietary changes, targeted supplementation, or lifestyle modifications are moving the needle.

1. If hs-CRP is persistently elevated (> 3.0 mg/L) despite interventions: Quarterly testing is appropriate, and additional workup — including fasting insulin, homocysteine, oxidized LDL, and gut permeability markers — should be considered.

Avoid drawing conclusions from a single data point. CRP rises acutely with any physiological stressor — a hard workout, poor sleep the night before, or even gum disease can temporarily push levels up. Context and trend lines matter far more than any isolated number.

How Often Should ESR Be Tested?

Erythrocyte sedimentation rate (ESR) is a closely related inflammatory marker that measures how quickly red blood cells settle in a tube. While hs-CRP reflects acute-phase inflammation with a short half-life (rising within hours and clearing within days), ESR is a slower, less specific signal that reflects changes over weeks. The two markers are complementary rather than redundant.

In functional medicine, ESR is most useful when:

• CRP is elevated but the source is unclear
• Autoimmune conditions such as rheumatoid arthritis, lupus, or polymyalgia rheumatica are suspected
• Tracking chronic, smoldering inflammation that CRP may miss due to its shorter window

Recommended testing frequency for ESR:

• No known inflammatory condition: Once per year alongside CRP is adequate for baseline screening.
• Known autoimmune condition or persistent CRP elevation: Every 3 months, co-ordered with CRP so that discordant results can prompt further investigation.
• Active flare of an inflammatory condition: Every 4–6 weeks until resolution.

Normal ESR ranges vary by age and sex (generally < 15 mm/hr for men under 50 and < 20 mm/hr for women under 50), but functional practitioners prioritize trends over single values. A study in Annals of the Rheumatic Diseases found that combining CRP and ESR improved prediction of inflammatory disease activity compared to either marker alone, reinforcing the value of testing them together rather than choosing one (Wolfe 1997; PMID: 9166011).

How Often Should Fasting Insulin Be Tested?

Fasting insulin is arguably the most underutilized metabolic biomarker in standard care — and one of the most powerful predictors of future CRP elevation. Insulin resistance drives the production of pro-inflammatory cytokines, particularly interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), which directly stimulate CRP synthesis in the liver. This means that if your CRP is elevated and your glucose looks normal, fasting insulin may be the hidden driver.

Conventional labs flag fasting insulin only above 25 µIU/mL. Functional medicine practitioners typically use a far tighter target:

A meta-analysis in Diabetologia (Shoelson et al., Journal of Clinical Investigation 2006; PMID: 16823477) outlined the mechanistic link between insulin resistance and inflammatory signaling, showing that IKKβ/NF-κB activation in insulin-resistant states directly upregulates cytokine production. Treating elevated fasting insulin is, in effect, a strategy for reducing CRP.

Recommended testing frequency for fasting insulin:

1. Baseline at your first comprehensive metabolic panel if not already done.
2. Annually if levels are optimal and metabolic health is stable.
3. Every 3–6 months if insulin is above 10 µIU/mL or CRP is elevated — because the two markers track each other closely and respond to the same interventions (dietary carbohydrate reduction, resistance training, sleep optimization).

If you are using a platform like Ones to interpret your lab results together, seeing fasting insulin alongside hs-CRP in the same analysis is far more actionable than either number in isolation.

How Often Should Cholesterol Ratio Be Tested?

The total cholesterol-to-HDL ratio (TC:HDL) is a composite cardiovascular risk variable that outperforms total cholesterol or LDL alone as a predictor of atherosclerosis. It encapsulates both the atherogenic burden (total cholesterol) and the protective capacity (HDL), making it particularly useful when LDL is borderline or when CRP is elevated despite normal LDL.

Optimal targets:

• TC:HDL ratio < 3.5 (ideal)
• TC:HDL ratio 3.5 – 5.0 (moderate risk; act)
• TC:HDL ratio > 5.0 (elevated risk; prioritize intervention)

The Framingham Heart Study data consistently show that the TC:HDL ratio predicts coronary heart disease risk more accurately than any single lipid fraction (Kinosian et al., Annals of Internal Medicine 1994; PMID: 8250461). When CRP is also elevated in a patient with a high TC:HDL ratio, the combined signal dramatically amplifies cardiovascular risk stratification.

Recommended testing frequency:

• Optimal ratio (< 3.5) with no other risk factors: Annually.
• Ratio 3.5 – 5.0 with elevated CRP: Every 6 months, and consider advanced lipid testing.
• Ratio > 5.0 or rapidly worsening trend: Every 3 months until a therapeutic response is confirmed.

How Often Should LDL Particle Number Be Tested?

Standard LDL cholesterol measures the amount of cholesterol carried inside LDL particles — but it says nothing about how many particles are circulating. LDL particle number (LDL-P), measured by nuclear magnetic resonance (NMR) spectroscopy, is a far more precise predictor of cardiovascular risk because smaller, denser LDL particles are more atherogenic and oxidize more readily — particularly in the context of elevated CRP.

The MESA study demonstrated that LDL-P predicted subclinical atherosclerosis progression significantly better than LDL-C, particularly in patients with metabolic syndrome — a population defined by insulin resistance and elevated inflammation (Cromwell et al., Journal of Clinical Lipidology 2007; PMID: 21291836).

Optimal LDL-P targets:

• < 1,000 nmol/L: Low risk
• 1,000 – 1,299 nmol/L: Moderate risk
• ≥ 1,300 nmol/L: High risk

Recommended testing frequency for LDL particle number:

• If you have had a standard lipid panel with normal LDL-C but elevated hs-CRP or a high TC:HDL ratio, order LDL-P once to establish your particle phenotype.
• If LDL-P is elevated, retest every 6 months while interventions are in place.
• If LDL-P is optimal and CRP is well-controlled, annual testing alongside your standard panel is sufficient.

Understanding your omega-3 index and cardiovascular risk markers is also valuable here — EPA and DHA reduce VLDL production and improve particle size, making omega-3 supplementation one of the most evidence-based strategies for improving LDL-P alongside hs-CRP.

What Drives CRP Up? Root-Cause Thinking

Before adjusting retest frequency, it helps to understand what commonly drives CRP into the moderate-to-high range:

• Visceral adiposity: Adipose tissue secretes IL-6, which signals the liver to produce CRP. A 1 kg reduction in visceral fat can meaningfully reduce hs-CRP.
• Insulin resistance: As outlined above, elevated fasting insulin is a direct upstream driver.
• Poor sleep: Even one night of sleep deprivation raises IL-6 and TNF-α. Chronic poor sleep produces chronically elevated CRP.
• Gut dysbiosis and intestinal permeability: Lipopolysaccharides (LPS) from gram-negative bacteria can translocate into circulation and trigger systemic inflammation.
• Nutritional deficiencies: Vitamin D deficiency, omega-3 insufficiency, and magnesium deficiency are each independently associated with higher hs-CRP.
• Chronic stress: The HPA axis and NF-κB inflammatory pathway interact bidirectionally — psychological stress elevates CRP through cortisol dysregulation.

What This Means for Your Formula

When Ones analyzes your lab data and wearable metrics, elevated hs-CRP is treated as a systemic signal, not a standalone number. The AI cross-references it against fasting insulin, TC:HDL ratio, sleep data, and other inflammatory markers before building your custom capsule formula.

For individuals with elevated CRP, the formula may include:

• Omega-3 (EPA/DHA): A meta-analysis of 68 trials found that omega-3 supplementation significantly reduced hs-CRP, IL-6, and TNF-α, with the largest effect in individuals with baseline CRP > 3.0 mg/L (Calder et al., Nutrition 2013). Ones uses a clinical-range EPA/DHA dose calibrated to your body weight and baseline inflammatory status — not a one-size-fits-all 1,000 mg softgel.

• Vitamin D3 + K2 (MK-7): Vitamin D receptors are expressed on immune cells including macrophages and dendritic cells. Deficiency is associated with elevated NF-κB activity and higher hs-CRP. Ones pairs D3 with MK-7 (menaquinone-7) to support calcium metabolism alongside immune modulation, at doses calibrated to your serum 25-OH-D level rather than a generic RDA.

• Liver Support System Blend: The liver synthesizes CRP — so hepatic detoxification capacity and oxidative stress in the liver directly influence baseline CRP levels. Ones' proprietary Liver Support blend is included when liver enzymes, alcohol use history, or metabolic risk factors suggest hepatic inflammatory burden.

The goal is not to suppress CRP artificially but to systematically address the upstream drivers that are keeping it elevated — so your retesting at 3 or 6 months shows a real trend, not a lucky outlier.

Key Takeaways

• hs-CRP should be retested every 3–6 months when elevated above 1.0 mg/L; annually is sufficient when optimal (< 0.5 mg/L).
• Never rely on a single CRP reading — two measurements 2 weeks apart are the clinical standard before making therapeutic decisions.
• ESR and hs-CRP are complementary, not redundant — order both when the inflammatory source is unclear or autoimmune conditions are suspected.
• Fasting insulin is a direct upstream driver of CRP — testing it alongside hs-CRP every 3–6 months reveals whether insulin resistance is the root cause.
• LDL particle number (LDL-P) and TC:HDL ratio add precision that standard LDL-C misses, especially when CRP is elevated with borderline cholesterol.
• Personalized supplementation targeting documented deficiencies — particularly omega-3, vitamin D, and liver-supportive nutrients — can produce measurable hs-CRP reductions within 6–12 weeks when dosed to clinical ranges.